<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64944</article-id><article-id pub-id-type="doi">10.7554/eLife.64944</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>eNOS-induced vascular barrier disruption in retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-215982"><name><surname>Ninchoji</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215983"><name><surname>Love</surname><given-names>Dominic T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-166607"><name><surname>Smith</surname><given-names>Ross O</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4239-3204</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215984"><name><surname>Hedlund</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-41846"><name><surname>Vestweber</surname><given-names>Dietmar</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3517-732X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-22561"><name><surname>Sessa</surname><given-names>William C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5759-1938</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-57798"><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4275-2000</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Immunology, Genetics and Pathology</institution>, <institution>Uppsala University</institution>, <addr-line><named-content content-type="city">Uppsala</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff2"><institution content-type="dept">Department of Vascular Cell Biology</institution>, <institution>Max Planck Institute for Molecular Biomedicine</institution>, <addr-line><named-content content-type="city">Münster</named-content></addr-line>, <country>Germany</country></aff><aff id="aff3"><institution content-type="dept">Pharmacology</institution>, <institution>Yale School of Medicine</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-57759"><name><surname>Koh</surname><given-names>Gou Young</given-names></name><role>Reviewing editor</role><aff><institution>Institute of Basic Science and Korea Advanced Institute of Science and Technology (KAIST)</institution>, <country>Korea (South), Republic of</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>nincho830@gmail.com</email> (TN);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>lena.welsh@igp.uu.se</email> (LC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>04</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e64944</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Ninchoji et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Ninchoji et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64944-v1.pdf"/><abstract><p><bold>Background:</bold> Hypoxia and consequent production of vascular endothelial growth factor A (VEGFA) promote blood vessel leakiness and edema in ocular diseases. Anti-VEGFA therapeutics may aggravate hypoxia; therefore, therapy development is needed.</p><p><bold>Methods:</bold> Oxygen-induced retinopathy was used as a model to test the role of nitric oxide (NO) in pathological neovascularization and vessel permeability. Suppression of NO formation was achieved chemically using L-NMMA, or genetically, in endothelial NO synthase (eNOS) serine to alanine (S1176A) mutant mice.</p><p><bold>Results:</bold> Suppression of NO formation resulted in reduced retinal neoangiogenesis. Remaining vascular tufts exhibited reduced vascular leakage through stabilized endothelial adherens junctions, manifested as reduced phosphorylation of vascular endothelial (VE)-cadherin Y685 in a c-Src-dependent manner. Treatment with a single dose of L-NMMA in established retinopathy restored the vascular barrier and prevented leakage.</p><p><bold>Conclusion:</bold> We conclude that NO destabilizes adherens junctions, resulting in vascular hyperpermeability, by converging with the VEGFA/VEGFR2/c-Src/VE-cadherin pathway.</p><p><bold>Funding:</bold> This study was supported by the Swedish Cancer foundation (19 0119 Pj 01 H), the Swedish Research Council (2020-01349), the Knut and Alice Wallenberg foundation (KAW 2020.0057) and a Fondation Leducq Transatlantic Network of Excellence Grant in Neurovascular Disease (17 CVD 03). KAW also supported LCW with a Wallenberg Scholar grant (2015.0275). WCS was supported by Grants R35 HL139945, P01 HL1070205, AHA MERIT Award.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012538</institution-id><institution>Swedish Cancer Foundation</institution></institution-wrap></funding-source><award-id>19 0119 Pj 01 H</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsrådet</institution></institution-wrap></funding-source><award-id>2020-01349</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source><award-id>KAW 2015.0030</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source><award-id>KAW.0275</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001674</institution-id><institution>Fondation Leducq</institution></institution-wrap></funding-source><award-id>17 CVD 03</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35 HL 139945</award-id><principal-award-recipient><name><surname>Sessa</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01HL 1070205</award-id><principal-award-recipient><name><surname>Sessa</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>Merit Award</award-id><principal-award-recipient><name><surname>Sessa</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Mouse husbandry and oxygen-induced retinopathy (OIR) challenge took place at Uppsala University,and the University board of animal experimentation approved all animal work for the studies (ethical permit 5.2.18-8927/16). Animal handling was in accordance to the ARVO statement for the Use of Animals in Ophthalmologic and Vision Research. Professional animal care was provided and overseen by University veterinarians.  Every effort was made to minimize suffering of the animal.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1-5. Source data files have also been deposited with Dryad: https://doi.org/10.5061/dryad.x69p8czhv</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Love D</collab><collab>Ninchoji T</collab><collab>Claesson-Welsh L</collab></person-group><year iso-8601-date="2021">2021</year><source>eNOS/NO and their role in modifying the vascular barrier in retinopathy - Source data</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.x69p8czhv">https://doi.org/10.5061/dryad.x69p8czhv</ext-link><comment>Dryad, 10.5061/dryad.x69p8czhv</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-64944-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>